Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Cakmak, Nese (1) Daumke, Oliver Prof. Dr. (1) Gavvovidis, Ioannis Dr. (1) Hinz, Michael Dr. (1) Höpken, Uta Elisabeth PD Dr. (1) Kettenmann, Helmut Prof. Dr. (1) Kieback, Elisa Dr. (1) Kopp, Joachim Dr. (2) Leisegang, Matthias Dr. (4) Lorenz, Felix Dr. (3) Müller, Gerd Dr. (1) Na, Il-Kang Dr. (1) Niendorf, Thoralf Prof. Dr. (1) Obenaus, Matthias (1) Pezzutto, Antonio Prof. Dr. (11) Poncette, Lucia (1) Purfürst, Bettina Dr. (1) Rhein, Simone Dr. (1) Uckert, Wolfgang Prof. Dr. (10) Waiczies, Helmar Dr. (1) Waiczies, Sonia Dr. (1) Willimsky, Gerald Dr. (2) Yilmaz, Zekiye Buket Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (8) 1997 (2) 1998 (4) 1999 (1) 2000 (4) 2003 (4) 2004 (2) 2005 (5) 2006 (2) 2007 (2) 2008 (1) 2010 (2) (-) 2011 (3) 2013 (1) 2014 (1) (-) 2015 (3) 2016 (1) 2017 (1) (-) 2019 (2) 2021 (1) Bioinformatics (1) Biology of Malignant Lymphomas (11) Genetics and Genomics of Cardiovascular Diseases (1) (-) Molecular Cell Biology and Gene Therapy (5) Molecular Immunology and Gene Therapy (14) (-) Molecular Immunotherapy (3) Proteome Dynamics (1) Signal Transduction in Tumor Cells (1) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) 8 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Molecular Cell Biology and Gene TherapyMolecular Immunotherapy201120152019 Sort: Result score Newest to oldest Oldest to newest April 01, 2019 in Leukemia Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies N. Çakmak-Görür J. Radke S. Rhein E. Schumann G. Willimsky F.L. Heppner T. Blankenstein A. Pezzutto January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein April 15, 2015 in Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein April 01, 2011 in Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
April 01, 2019 in Leukemia Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies N. Çakmak-Görür J. Radke S. Rhein E. Schumann G. Willimsky F.L. Heppner T. Blankenstein A. Pezzutto
January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
April 15, 2015 in Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann
April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
April 01, 2011 in Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
